"Science and innovation can only make a difference if it is applied outside of the laboratories and reaches people worldwide. This partnership is a major step forward to enable access to mRNA technology and promote collaborations in the Asia-Pacific region," said Prof. Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "Australia provides excellent academic research, and we are looking forward to collaborating with world-class scientists and researchers to strengthen Australia's mRNA ecosystem and to jointly develop potential novel treatments and vaccines for people worldwide."
As part of this collaboration, the State of Victoria and BioNTech will establish a research and innovation center, directed in partnership with the State, with the aim to support Australia's mRNA ecosystem by curating projects and to determine their potential transition into preclinical and clinical development, supported by BioNTech's advice and know-how. The partnership will also include the research and development of experimental therapies including mRNA-based product candidates for indications with high unmet medical need, for instance in oncology. BioNTech will support the R&D efforts on a project-by-project basis with the Company's expertise in mRNA research and clinical development of potential new products.
In addition to driving innovative translational research, BioNTech will also support local delivery by developing and commissioning an end-to-end clinical-scale manufacturing facility for mRNA-based medicines and product candidates in Melbourne, Victoria. BioNTech has developed the BioNTainer, a mobile modular manufacturing unit requiring limited space for operation, allowing for timely and flexible local production of different mRNA-based constructs and products across a variety of indications, and expects to create hundreds of jobs during construction and operation in Melbourne.
"We at BioNTech are committed to global public health, and as we continue to expand internationally, we look forward to working jointly to drive the development of innovative medicines," said Dr. Sierk Poetting, COO of BioNTech. "Our BioNTainers are designed as turnkey manufacturing sites for mRNA-based medicines and product candidates. In Melbourne, our BioNTainers will allow for an end-to-end production including fill and finish for clinical-scale manufacturing of mRNA candidates, once approved."
Read also: Pfizer-BioNTech Omicron retooled booster authorised in Canada
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.